MGNX experienced a severe cash burn with cash and equivalents dropping from $182.8M to $57.2M while total liabilities increased by 38.2%, creating potential liquidity concerns for this clinical-stage biotech.
The company burned through over $125 million in cash while simultaneously increasing its debt burden, reducing its financial runway significantly. This cash depletion rate raises questions about the company's ability to fund ongoing clinical trials and operations without additional financing, particularly concerning given the clinical hold mentioned on their LINNET study.
MGNX's financial position deteriorated meaningfully with cash reserves declining 68.7% to $57.2M while total liabilities grew substantially to $201.3M. Operating cash flow worsened to -$81.0M from -$68.4M, though the company did reduce R&D expenses by 16.9% and improved operating losses. The combination of accelerating cash burn, reduced equity cushion (down 52.1%), and increased liabilities signals potential funding pressures ahead for this clinical-stage company.
Cash declined 68.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Capex reduced 48.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Liabilities grew 38.2% — significant increase in debt or obligations, assess impact on financial flexibility.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Current liabilities reduced — improved short-term financial position and working capital health.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
R&D spending cut 16.9% — could signal cost discipline or concerning reduction in innovation investment.
Net income declined 11.4% — review whether driven by operations, interest costs, or non-recurring items.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →